Accelerate Diagnostics, Inc. (NASDAQ:AXDX - Get Free Report) CEO Jack Phillips sold 15,887 shares of the stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $0.88, for a total transaction of $13,980.56. Following the transaction, the chief executive officer now directly owns 96,343 shares of the company's stock, valued at $84,781.84. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Jack Phillips also recently made the following trade(s):
- On Thursday, February 1st, Jack Phillips sold 494 shares of Accelerate Diagnostics stock. The shares were sold at an average price of $1.30, for a total transaction of $642.20.
Accelerate Diagnostics Stock Performance
AXDX opened at $0.84 on Friday. The company has a market cap of $12.20 million, a PE ratio of -0.17 and a beta of 0.52. The company has a 50 day moving average of $1.07 and a 200 day moving average of $3.49. Accelerate Diagnostics, Inc. has a 12 month low of $0.83 and a 12 month high of $11.90.
Hedge Funds Weigh In On Accelerate Diagnostics
Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of Accelerate Diagnostics by 22.6% in the third quarter. Vanguard Group Inc. now owns 2,825,643 shares of the medical research company's stock valued at $4,295,000 after acquiring an additional 520,656 shares during the period. Baird Financial Group Inc. increased its position in shares of Accelerate Diagnostics by 15.5% in the first quarter. Baird Financial Group Inc. now owns 1,741,547 shares of the medical research company's stock valued at $2,508,000 after acquiring an additional 233,478 shares during the period. State Street Corp increased its position in shares of Accelerate Diagnostics by 12.9% in the first quarter. State Street Corp now owns 1,234,706 shares of the medical research company's stock valued at $1,778,000 after acquiring an additional 140,883 shares during the period. Griffin Asset Management Inc. increased its position in shares of Accelerate Diagnostics by 3.0% in the fourth quarter. Griffin Asset Management Inc. now owns 1,219,724 shares of the medical research company's stock valued at $4,781,000 after acquiring an additional 35,146 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Accelerate Diagnostics by 31.8% in the second quarter. Geode Capital Management LLC now owns 655,906 shares of the medical research company's stock valued at $531,000 after acquiring an additional 158,383 shares during the period. Hedge funds and other institutional investors own 17.14% of the company's stock.
Analysts Set New Price Targets
READ THIS – If You Missed Out On The AI Boom
From Banyan Hill Publishing | Ad
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy.
Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
Click on Adam's shiny forehead for more details.
A number of research firms have recently weighed in on AXDX. William Blair reissued an "outperform" rating on shares of Accelerate Diagnostics in a research report on Tuesday. StockNews.com started coverage on shares of Accelerate Diagnostics in a report on Thursday. They issued a "hold" rating for the company. Finally, Craig Hallum cut their price objective on shares of Accelerate Diagnostics from $2.00 to $1.00 and set a "hold" rating for the company in a report on Monday, April 1st.
Get Our Latest Report on Accelerate Diagnostics
Accelerate Diagnostics Company Profile
(
Get Free Report)
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
